{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:41:15Z","timestamp":1791438075205,"version":"4.3.3"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,6]],"date-time":"2027-08-06T00:00:00Z","timestamp":1817510400000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA225517"],"award-info":[{"award-number":["P01 CA225517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jid.2026.01.021","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:14:23Z","timestamp":1770164063000},"page":"2168-2175.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical benefit of adding radiation for immune checkpoint inhibitor-refractory Merkel cell carcinoma: A 27-patient analysis"],"prefix":"10.1016","volume":"146","author":[{"given":"Rian","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita A.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Ch\u2019en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore A.","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Hippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Bhakuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lachance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Y.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-963X","authenticated-orcid":false,"given":"Paul","family":"Nghiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2026.01.021_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.77","article-title":"Merkel cell carcinoma","volume":"3","author":"Becker","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2026.01.021_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS9598","article-title":"The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1\u2013refractory Merkel cell carcinoma","volume":"43","author":"Bhakuni","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jid.2026.01.021_bib3","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO-24-02138","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic merkel cell carcinoma: a nonrandomized, open-label, international, multicenter phase I\/II study","volume":"43","author":"Bhatia","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jid.2026.01.021_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3389\/fonc.2019.00223","article-title":"Rescue of immunotherapy-refractory metastatic Merkel cell carcinoma with conventionally fractionated radiotherapy and concurrent pembrolizumab","volume":"9","author":"Bloom","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2026.01.021_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jid.2026.01.021_bib6","article-title":"Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials","volume":"13","author":"Ch'en","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jid.2026.01.021_bib7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.adro.2020.07.003","article-title":"Postoperative, single-fraction radiation therapy in Merkel cell carcinoma of the head and neck","volume":"5","author":"Cook","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.jid.2026.01.021_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jid.2026.01.021_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000674","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial","volume":"8","author":"D'Angelo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jid.2026.01.021_bib10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.semnuclmed.2022.06.001","article-title":"Response evaluation following radiation therapy with 18F-FDG PET\/CT: common variants of radiation-induced changes and potential pitfalls","volume":"52","author":"Dejanovic","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.jid.2026.01.021_bib11","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jaad.2025.01.099","article-title":"Adjuvant single-fraction radiotherapy to the resected primary tumor site and stage IIIA regional disease results in high locoregional control in Merkel cell carcinoma in a single-institution retrospective study","volume":"92","author":"Dykstra","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2026.01.021_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/jpm13050841","article-title":"Introducing radiotherapy in metastatic Merkel cell carcinoma patients with limited progression on avelumab: an effective step against primary and secondary immune resistance?","volume":"13","author":"Ferini","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.jid.2026.01.021_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jid.2026.01.021_bib14","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1245\/s10434-016-5266-4","article-title":"Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system","volume":"23","author":"Harms","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jid.2026.01.021_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2024.06.1086","article-title":"LB914 A single postoperative dose of radiotherapy (8 Gy) has comparable efficacy to a standard 5-week course for localized Merkel cell carcinoma (MCC)","volume":"144","author":"Huynh","year":"2024","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jid.2026.01.021_bib16","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/cam4.458","article-title":"Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma","volume":"4","author":"Iyer","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.jid.2026.01.021_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-016-0156-7","article-title":"Current clinical trials testing the combination of immunotherapy with radiotherapy","volume":"4","author":"Kang","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jid.2026.01.021_bib18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","article-title":"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.01.021_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jid.2026.01.021_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jid.2026.01.021_bib21","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/cam4.2781","article-title":"Patterns of distant metastases in 215 Merkel cell carcinoma patients: implications for prognosis and surveillance","volume":"9","author":"Lewis","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.jid.2026.01.021_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/pst.1628","article-title":"Wilcoxon's signed-rank statistic: what null hypothesis and why it matters","volume":"13","author":"Li","year":"2014","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jid.2026.01.021_bib23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","article-title":"Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis","volume":"158","author":"McEvoy","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2026.01.021_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9618","article-title":"TRICK-MCC: A proof-of-concept, investigator-initiated study of combination therapy with anti\u2013PD-1, anti\u2013LAG-3, and anti\u2013TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma","volume":"42","author":"Miller","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jid.2026.01.021_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002478","article-title":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","volume":"9","author":"Nghiem","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jid.2026.01.021_bib26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jid.2026.01.021_bib27","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.01.021_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jid.2026.01.021_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijrobp.2020.08.025","article-title":"Use of multi-site radiation therapy for systemic disease control","volume":"109","author":"Patel","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jid.2026.01.021_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6004\/jnccn.2024.0002","article-title":"NCCN guidelines\u00ae insights: merkel cell carcinoma, version 1.2024","volume":"22","author":"Schmults","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jid.2026.01.021_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.intimp.2017.03.015","article-title":"Primary and acquired resistance to PD-1\/PD-L1 blockade in cancer treatment","volume":"46","author":"Wang","year":"2017","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26000709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26000709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:28:33Z","timestamp":1786037313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X26000709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022202X26000709"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2026.01.021","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical benefit of adding radiation for immune checkpoint inhibitor-refractory Merkel cell carcinoma: A 27-patient analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2026.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}